All sponsors

Ascentage Pharma Group Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-37
RECRUITING14
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO64%

Delay Index: of 14 active trials registered more than a year ago, 9 have moved their primary completion (readout) date by more than 6 months since first registration (median +18.9 months). See all sponsors →

Open Ascentage Pharma Group Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
APG-2575
NCT04494503
P1/2RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma1232024-10-20
Phase 1b: APG-115+pembrolizumab
NCT03611868
P1/2Active, not recruitingUnresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma2302025-12-30 (+63 mo)
APG-115
NCT04785196
P1/2RecruitingLiposarcoma; Advanced Solid Tumor952026-04 (+24 mo)
APG-2575
NCT06182969
P1/2RecruitingSLE402026-04
APG-115
NCT04496349
P2RecruitingT-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma782026-05-31 (+58 mo)
APG2575
NCT05147467
P2RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma752026-12 (+38 mo)
lisaftoclax +BTK inhibitor
NCT06104566
P3RecruitingCLL/SLL4002026-12-31 (+14 mo)
Olverembatinib
NCT06640361
P3RecruitingGIST402027-03-31
APG-115
NCT05701306
P1/2RecruitingNeuroblastoma; Solid Tumor1002027-06-01 (+12 mo)
POLARIS-2
NCT06423911
P3RecruitingChronic Myeloid Leukemia; CML3332027-06-30 (+19 mo)
Lisaftoclax (APG-2575)
NCT06319456
P3RecruitingCLL/SLL3442027-08
Olverembatinib
NCT06051409
P3RecruitingPh+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive3502027-12-31 (+36 mo)
APG-2575(Lisaftoclax )
NCT06389292
P3RecruitingAcute Myeloid Leukemia4862028-05-25
Lisaftoclax (APG-2575)
NCT04501120
P1/2RecruitingRelapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy6822028-09 (+73 mo)
Lisaftoclax (APG-2575)
NCT06641414
P3RecruitingHigher-risk Myelodysplastic Syndrome4902029-06